drugset / Trial / NCT03775070

Simvastatin Therapy in Patients With Dilated Cardiomyopathy.

NCT03775070

Phase 2 Completed 8 enrolled National Taiwan University Hospital
NaSingle-groupOpen-labelTreatment

Summary

Dilated cardiomyopathy (DCM) is the most common childhood cardiomyopathy and is associated with significant early morbidity and mortality. About half of patients die or require heart transplantation within 5 years of diagnosis. The medical therapy for DCM with heart failure includes anti-congestive medications and antiplatelet therapy. Those who fail to improve within the first year of diagnosis usually deteriorated even upon aggressive anti-congestive medications. The investigators had conducted precision-medicine-based approach to provide strategic approach as drug repurposing to identify new treatments. The investigators have identified the beneficial effects from a statin, simvastatin, to restore the cardiac contractility. The investigators would further assess the efficacy of simvastatin to improve the cardiac function in patients with DCM.

Timeline

Start
2019-01-17
Primary completion
2022-07-31
Completion
2022-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Simvastatin Small molecule 0.5 mg/kg